創薬アウトソーシングの世界市場...市場調査レポートについてご紹介

【英文タイトル】Drug Discovery Outsourcing Market Forecast 2015-2025 : Opportunities for Leading Companies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 The Drug Discovery Outsourcing Market Overview
1.2 Drug Discovery Outsourcing Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports

2. An Introduction to Drug Discovery Outsourcing
2.1 What is Outsourcing?
2.2 What is Drug Discovery Outsourcing?
2.3 Why Outsource Drug Discovery?
2.4 A Common Drug Discovery Model Includes Pharma Collaborations with Academia
2.5 The Outsource Model for Drug Development Increases Innovation
2.6 Outsourced Processes in Drug Discovery
2.7 Challenges with Drug Discovery Outsourcing
2.8 Emerging Markets are a Popular Destination for CROs
2.9 Strategic Partnerships to Acquisitions
2.10 Recent Drug Development Outsourcing Agreements
2.11 Glossary of Terms Related to Drug Discovery Outsourcing

3. Global Drug Discovery Outsourcing Market and Service Area Submarkets, 2015-2025
3.1 Drug Discovery Outsourcing: Global Market Overview
3.2 The Global Drug Discovery Outsourcing Market Sectors
3.3 The Global Drug Discovery Outsourcing Market by Sector, 2014
3.4 The Global Drug Discovery Outsourcing Market by Sector, 2015-2025
3.5 The Changing Market Shares by Sector, 2015-2025
3.6 The Global Chemistry Services Outsourcing Market, 2014
3.6.1 Libraries
3.6.2 Building Blocks
3.6.3 Compound Synthesis
3.6.4 The Global Chemistry Services Outsourcing Market Forecast, 2015-2025
3.7 The Global Biology Services Outsourcing Market, 2014
3.7.1 Target Identification
3.7.2 Target Validation
3.7.3 The Global Biology Services Outsourcing Market Forecast, 2015-2025
3.8 The Global Lead Optimisation Market, 2014
3.8.1 ADMET Screening: Prevents Late Stage Failure of Clinical Trials
3.8.2 The Global Lead Optimisation Market Forecast, 2015-2025
3.9 The Global Lead Identification and Screening Outsourcing Market, 2014
3.9.1 Methods of Screening in Drug Discovery
3.9.2 Primary Screening
3.9.3 The Global Lead Identification and Screening Outsourcing Market Forecast, 2015-2025

4. The Leading National Markets in the Drug Discovery Outsourcing Markets 2015-2025
4.1 Drug Discovery Outsourcing Overview
4.2 The Leading National Markets in the Drug Discovery Outsourcing Market, 2014
4.3 The Leading National Markets in the Drug Discovery Outsourcing Market, 2015-2025
4.4 The Changing Market Shares of the Leading National Markets in the Drug Discovery
Outsourcing Market, 2015-2025
4.5 CAGRS of the Leading National Markets in the Drug Discovery Outsourcing Market, 2015-2025
4.6 The US Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.7 The EU5 Drug Discovery Outsourcing Market by Region, 2014
4.7.1 The EU5 Drug Discovery Outsourcing Market Forecast, 2015-2025
4.7.2 CAGRS by EU5 Region, 2015-2025
4.7.3 The EU5 Changing Market Shares by Country 2015-2025
4.7.3.1 The German Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.7.3.2 The UK Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.7.3.3 The French Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.7.3.4 The Italian Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.7.3.5 The Spanish Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.8 The Japanese Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.9 The Chinese Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.9.1 Challenges to China’s Growth
4.10 The Indian Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.11 The Brazilian Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.12 The Russian Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.13 The South Korean Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.14 The Mexican Drug Discovery Outsourcing Market Sales Forecast, 2015-2025
4.15 The Rest of the World Drug Discovery Outsourcing Market Sales Forecast, 2015-2025

5. Leading Companies in the Drug Discovery Outsourcing Market in 2015
5.1 Drug Discovery Outsourcing: A Fragmented and Growing Marketplace
5.2 Characteristics of Leading Contract Research Organisations
5.2.1 A Highly Quality Workforce
5.2.2 Emphasis on Intellectual Property Protection
5.2.3 Long Term Working Relationship
5.2.4 Success in Project Completion
5.2.5 Internal Drug Discovery Programmes
5.3 Service Offerings of Leading Companies in the Drug Discovery Outsourcing Market
5.4 Albany Molecular Research (AMRI)
5.4.1 Sales and Recent Financial Performance, 2011-2013
5.4.2 AMRI’s Drug Discovery Services
5.4.3 Internal Portfolio of Drug Discovery and Development Programme Collaborations
5.5 Aptuit
5.5.1 INDIGO: Accelerating Early Drug Candidates
5.5.2 Aptuit Clinical Trial Supplies
5.5.3 Strategic Partnerships, Acquisitions and Divestitures
5.5.3.1 Divestiture of Aseptic Clinical Manufacturing
5.5.3.2 Aptuit’s Extended Partnership with GSK for Verona Centre
5.5.3.3 Partnership with Siena Biotech
5.5.3.4 Partnership with Laurus Labs
5.6 Charles River Laboratories
5.6.1 Sales and Recent Financial Performance, 2011-2013
5.6.2 Charles River Laboratories: An External Acquisition Strategy
5.6.2.1 Acquisition of ChanTest
5.6.2.2 Acquisition of Galapagos’ CRO Services Division (BioFocus and Argenta)
5.6.2.3 Acquisition of VivoPath
5.6.3 Charles River Laboratories: Revenue and Financial Analysis, 2014
5.6.3.1 Charles River Laboratories: Financial Performance by Business Segment, 2013-2014
5.6.4 Charles River Laboratories Sales Forecast, 2015-2025
5.7 Covance (Acquired by LabCorp)
5.7.1 Covance: Historical Revenue and Financial Performance, 2010-2013
5.7.2 Covance: Early Stage Discovery Efforts
5.7.3 Agreement with Sanofi
5.7.4 Agreement with Kellogg Company
5.7.5 Agreement with BioPontis Alliance
5.7.6 Agreement with Indiana Clinical and Translational Sciences Institute (CTSI)
5.7.7 Agreement with Eli Lilly
5.8 Cyprotex
5.8.1 Historical Revenue and Financial Performance, 2011-2013
5.8.2 Cyprotex: Revenue by Region, 2013
5.8.3 Cyprotex: Revenue Analysis and Forecast 2015-2025
5.9 Domainex
5.9.1 Drug Pipeline
5.9.2 TBK1/ IKKε Inhibitors
5.9.3 Methyltransferase (KMTS) Inhibitors
5.10 Evotec
5.10.1 Strategic Action Plan
5.10.2 Evotec: Revenue and Financial Analysis, 2010-2013
5.10.3 EVT Integrate and EVT Innovate
5.10.4 Partnerships with Pharma for Drug Discovery
5.10.4.1 Partnership with Sanofi
5.10.4.2 Extended Partnership with Evotec
5.10.4.3 Partnership with Johnson & Johnson
5.10.4.4 Partnership with AstraZeneca
5.10.4.5 Partnership with Bayer Pharma
5.10.4.6 Partnership with Boehringer Ingelheim Pharma
5.10.4.7 Collaboration with CHDI
5.10.4.8 Collaboration with Janssen
5.10.4.9 Collaboration with MedImmune
5.10.4.10 Collaboration with UCB Pharma
5.10.5 Evotec Sales Forecast, 2015-2025
5.11 GenScript
5.11.1 GenScript: Agreements and Partnerships
5.12 Pharmaceutical Product Development (PPD)
5.12.1 PPD: Agreements, Strategic Partnerships and Private Merger
5.12.1.1 Acquisition of Acurian
5.12.1.2 Partnership with Elan
5.12.1.3 Partnership with GSK
5.13 Quintiles
5.13.1Quintiles: Historical Revenue and Financial Performance, 2009-2013
5.13.2 Development Deal With Merck
5.13.3 Quintiles: Acquisition of Advion Bioanalytical Labs
5.13.4 Quintiles: Shedding Jobs
5.13.5 Quintiles Sales Forecast, 2015-2025
5.14 Selcia
5.14.1 A Strong Natural Product Chemistry Track Record
5.14.2 Initiative with the University of Edinburgh
5.14.3 Collaboration with Cantab
5.15 Viva Biotech
5.15.1 GPCR Targeted Discovery Programs
5.15.2 Antibody Therapeutics Discovery
5.16 WIL Research Laboratories
5.16.1 Focus on Preclinical Research
5.16.2 Acquisition of Ricerca Biosciences LLC
5.16.3 Acquisition of Midwest BioResearch
5.17 WuXi Apptec
5.17.1WuXi AppTec: Service Offerings
5.17.2 Acquisition of NextCODE Health
5.17.3 WuXi AppTec: Historical Revenue and Financial Performance, 2009-2013
5.17.4 WuXi AppTec: Laboratory Services Sales Forecast, 2015-2025

6. Qualitative Analysis of the Drug Discovery Outsourcing Market, 2015-2025
6.1 Drivers and Restraints in the Drug Discovery Outsourcing Market, 2015-2025
6.2 SWOT Analysis of the Drug Discovery Outsourcing Market, 2015-2025
6.3 Strengths
6.3.1 Cost Reduction: A Central Driver for Outsourcing
6.3.2 Accelerating the Discovery of Drug Candidates
6.3.3 Growth of Virtual Pharma Companies
6.3.4 Reduction in R&D capacity Within Big Pharma
6.4 Weaknesses
6.4.1 Slowing Trajectory of Growth for R&D Spending
6.4.2 Increasingly Saturated Market Requires Companies to Quickly Evolve
6.5 Opportunities
6.5.1 The Available Scope for the Expansion of CROs
6.5.2 Targeted Therapies: Advances in Biologics and Orphan Drugs
6.5.3 Increasing Development of Biologics and Biosimilars
6.6 Threats
6.6.1 A Competitive Market is Increasing Consolidation
6.6.2 Threat of Private Public Alliances
6.6.3 Intellectual Property Leaks
6.6.4 Challenges of Technology Transfer
6.7 Porter’s Five Force Analysis of the Drug Discovery Outsourcing Market
6.7.1 Threat of New Entrants: Medium
6.7.2 Power of Suppliers: Medium
6.7.3 Threat of Substitutes: Medium
6.7.4 Power of Buyers: High
6.7.5 Rivalry Among Competitors: High

7. Expert Opinions
7.1 Interview with Dr Mario Polywka, Chief Operating Officer, Evotec
7.1.1 Bridging the Gap Between Academia and Big Pharma
7.1.2 Evotec: Specialises in Certain Disease Therapies
7.1.3 Complete Drug Discovery Outsourcing: A Growing Trend
7.1.4 Strategies for Drug Discovery Outsourcing Expansion
7.1.5 Building Trust in Collaborations
7.1.6 Evotec: Proven Track Record of Success
7.2 Dr John Davis, Director of Discovery and Dave Roberts, Business Development Director, Radiochemistry, Selcia
7.2.1 Growth in the Full Spectrum of Outsourcing Services
7.2.2 Natural Products: Increasing Source of Drug Discovery
7.2.3 Strong Pool of Early Drug Candidates
7.2.4 Overcoming Drug Discovery Challenges using Drug Discovery
7.2.5 Selcia: Regional Base of Clients
7.2.6 Drug Discovery and Emerging Technologies
7.2.7 MedChemPlus Projects
7.2.8 Varied Customer Base
7.2.9 CROs: Improving Drug Discovery Productivity Levels?
7.3 Interview with Dr. Paul Overton, Executive VP, Business Development & Marketing, Aptuit
7.3.1 End-to-End Drug Discovery Integration Growth
7.3.2 Whole Project Externalisation
7.3.3 Drug Discovery Outsourcing: One of Aptuit’s Fastest Growing Services
7.3.4 Aptuit INDiGO® Program
7.3.5 Aptuit Implementation Drug Discovery Acquisitions
7.3.6 Aptuit: Adding the Intellectual Capabilities for Drug Discovery
7.3.7 Several Partners in the Drug Discovery Model

8. Conclusion
8.1 Market Overview
8.2 Lead Optimisation will be the Fastest Growing Sector
8.3 The Drug Discovery Outsourcing Market in Emerging Market Show Huge Gains
8.4 Continued Growth in Alliances and Collaborations
8.5 Concluding Remarks


【レポート販売概要】

■ タイトル:創薬アウトソーシングの世界市場
■ 英文:Drug Discovery Outsourcing Market Forecast 2015-2025 : Opportunities for Leading Companies
■ 発行日:2015年3月
■ 調査会社:visiongain
■ 商品コード:VGAIN5040807
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。